First published by the ACFP in 2013, the Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta (often referred to as the Pricing Document) compares pricing of commonly prescribed drugs in Alberta. Developed and produced by the leadership and discernment of Dr. Michael Kolber and pharmacists, Jayson Lee, and Tony Nickonchuk, the Pricing Doc has become an invaluable tool for primary care providers and family physicians when seeking affordable drug choices for their patients. The ACFP and the PEER team are happy to provide a dynamic and up-to-date web application of the Pricing Document with the assistance of data updates from the Alberta Blue Cross.
Maximum Allowable Cost (MAC Pricing): In Alberta, effective December 12, 2019, all government sponsored drug programs will apply Maximum Allowable Cost (MAC) pricing to ACE Inhibitors, statins and dihydropyridine Calcium Channel Blockers. Any drug in that class that is on the Alberta Drug Benefit List will continue to be covered, but only at the MAC price set for each class. If the price of the prescribed drug is more than the MAC price, the patient will pay the difference out-of-pocket. For ACE inhibitors, MAC pricing does not apply to pediatrics, heart failure BID dosing, and breastfeeding patients. For more information, please see the table of MAC medications: Maximum Allowable Cost (MAC) Policy — Expanded Drug Categories and Alberta Blue Cross bulletin.